SLC22A12 and hyperuricemia: Although high selective URAT1 inhibitor, such as lesinurad and verinurad, is developed as a new therapeutic agent of hyperuricemia, the safety and true effect of treat-to-target trials are still not enough (Tausche et al., 2017).